Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Bausch & Lomb Incorporated
483
•Bausch & Lomb Incorporated•February 25, 2016

Bausch & Lomb Incorporated – FDA 483, Feb 25, 2016

Record Details

This FDA Form 483 document details observations from an inspection, indicating significant deficiencies in the facility's quality control and manufacturing processes.

**Key Violations and Observations:**

* **Inadequate Investigations:** Written records of investigations into unexplained discrepancies lack conclusions and follow-up. Investigations are incomplete, and potential root causes are not consistently identified. Specifically, there was no scientific justification for root causes assigned to action level excursion investigations for non-viable particle testing on aseptic filling lines. An investigation report submitted was incomplete, failing to identify the root cause or propose effective corrective actions. No investigation was conducted into a particle count test failure for a post-simulated use test for a submission stability batch. Nonconformance Investigation Report (NCR) #540800, concerning leaking HEPA filters found in October 2015, was deemed inadequate. * **Environmental Monitoring Deficiencies:** Environmental sampling is not conducted under dynamic conditions, contrary to SOP 72-001, section 6.5.2. The written environmental sampling program is inadequate due to a lack of scientific justification for sampling locations. * **Airflow and Particulate Control Issues:** Smoke studies are insufficient to demonstrate unidirectional airflow and sweeping action over and away from critical processing areas under dynamic conditions in the ophthalmic filling area's classified areas. There is no assurance that the firm's current method for monitoring non-viable particulates during aseptic processing is reliable. *

Company
Bausch & Lomb Incorporated
Inspection date
February 25, 2016
Product type
Drugs
Office
Florida District Office
People
  • Michael H. Tollon (Approval Manager)
  • Denise M. Digiulio (Federal Agencies)
View Company Profile

ID · 45cce76a-463f-4655-81fb-507fb05a3d8c

Violation Codes6
FD&C Act 905(j)21 CFR 21021 CFR 211FD&C Act 801(a)(3)21 CFR 331(c)21 U.S.C. 324(a)(4)

Full citation text and observation details available on the Dashboard.

Other documents for Bausch & Lomb Incorporated
  • 483 - 2026-03-20March 20, 2026
  • 483 - 2017-05-26May 26, 2017
  • EIR - 2017-05-26May 26, 2017
  • EIR - 2016-02-25February 25, 2016
  • WARNING_LETTER - 2012-10-02October 2, 2012

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bausch & Lomb Incorporated
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.